inveox supports Partners in COVID-19 Crisis

Med-Tech Company from Munich sending SARS-COV-2 test kits, personal protective equipment (PPE), and disinfectants to clinics and labs worldwide

22. April 2020, Munich – inveox GmbH in Garching (north of Munich) is now supplying medical facilities with sample kits, respiratory masks, personal protective equipment (PPE), and PCR kits that are needed to diagnose SARS-COV-2 and to protect personnel. The product range includes SARS-COV-2 sample kits with Universal Transport Medium (UTM) for throat and nose samples as well as FFP2 and FFP3 respiratory protection masks, surgical masks, protective goggles, protective suits, nitrile gloves, disinfectants and PCR kits for the qualitative detection of nucleic acid from SARS-CoV-2.

The young company has built a reputation in histopathology and cancer diagnostics, yet inveox has recently also started shipping up to one million test kits, one million FFP2 masks and three million surgical masks per week (as of April 2020) throughout the world. In a swift reaction to the global pandemic, the company was able to direct some of its supply chains to help the global shortage of medical supplies. At the same time it continues its mission to automate sample entry in histopathology labs. Among the first customers of this new venture are currently around 300 chains of health clinics, labs and medical centers in Europe and the USA.

One of the first customers to receive inveox’s new products is Dr. Wesley Long, MD, PhD, Medical Director of Diagnostic Microbiology in Houston, Texas, who states: “In these challenging times of the global COVID-19 pandemic, the importance of personal relationships with reliable, trustworthy individuals and vendors who can deliver on their promises cannot be stressed enough. I appreciate my friendship with inveox and their assistance with securing these needed supplies.”

For inveox Founders and Managing Partners Maria and Dominik Sievert, rapid action to expand and adjust some of their supply chains allows them to assist their medical partners in new ways, while continuing steady on their mission to improve healthcare: “The supply of swab tests and personal protection equipment by us ensures that medical personnel can continue to work on combating the COVID-19 virus. While the crisis with all its effects is currently unfolding on a daily basis, one thing is certain for us: The true heroes these days are our customers. The specialists, medical personnel and laboratory staff who are working tirelessly. We would like to thank them from the bottom of our hearts, both on behalf of the inveox team and as individuals.”

More information available at: www.inveox.de/sampling

About inveox GmbH

inveox GmbH, founded in Munich in 2017, develops systems for the digitization, automation and networking of pathology laboratories. The aim is to increase the safety and reliability of cancer diagnoses, while at the same time improving the efficiency and profitability of laboratories and tapping the potential for personalized diagnostics based on Big Data and artificial intelligence.

Since its founding, inveox has won numerous awards and was part of several accelerators of renowned companies, such as “Digital Health” (Roche Diagnostics / Plug&Play) and the Texas Medical Center Accelerator 2019 in Houston, Texas. The same year it was founded, inveox was voted “Start-up of the Year2017” by Für-Gründer magazine, it was on the Forbes list of the “100 most promising startups 2018” and was a finalist in the German Innovation Prize in 2019. At the end of 2018, inveox opened a subsidiary in Krakow (Poland) and in 2019 became a member of the World Economic Forum. It currently has a combined work force of 89 colleagues in both offices.

Press contact:

Tina Holtz | Head of Marketing & Communications

tina.holtz@inveox.com| +49 (0) 157 92348482

Lichtenbergstr. 8 85748 Garching bei München
Deutschland

published on 20th kwietnia 2020